Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443430 · ClinicalTrials.gov registry record · Phase 4
Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
A Phase 4 study of Juvenile Idiopathic Arthritis and Juvenile Rheumatoid Arthritis, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 85
- Enrollment target
- 15
- Study locations
NCT00443430: Completed Phase 4 study of Juvenile Idiopathic Arthritis and Juvenile Rheumatoid Arthritis, sponsored by Seattle Children's Hospital.
NCT00443430 is a Phase 4 study of Juvenile Idiopathic Arthritis and Juvenile Rheumatoid Arthritis that has completed, run by Seattle Children's Hospital. The registered enrollment target is 85 participants, below the 292-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (71% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00443430, a Phase 4 study of Juvenile Idiopathic Arthritis and Juvenile Rheumatoid Arthritis, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 85 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to compare two aggressive drug regimens for children with poly-juvenile idiopathic arthritis (JIA) and extended oligo JIA.
Conditions Studied
Interventions
- DRUG methotrexate
- DRUG methotrexate - etanercept - prednisolone arm
Study Locations (15)
California
- Stanford University Medical Center - Palo Alto
- Rady Children's Hospital - San Diego
- University of California San Francisco Medical Center - San Francisco
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic Foundation - Cleveland
- Children's Hospital of Columbus - Columbus
New York
- Schneider Children's Hospital - New Hyde Park
- Children's Hospital at Montefiore - The Bronx
Massachusetts
- Children's Hospital of Boston - Boston
New Jersey
- Hackensack University Medical Center - Hackensack
North Carolina
- Duke University - Durham
Oklahoma
- Oklahoma University Health Science Center - Oklahoma City
Texas
- Texas Scottish Rite Hospital - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-10 |
| Phase | Phase 4 |
What the finished NCT00443430 record still lists
NCT00443430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 292-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (71% lower).
The record links to 3 conditions, with Juvenile Idiopathic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which methotrexate is the first listed.
NCT00443430 lists 15 locations in 10 states (California, Ohio, New York).
Frequently Asked Questions
What is clinical trial NCT00443430 about?
NCT00443430 is a clinical study titled "Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis". The purpose of this study is to compare two aggressive drug regimens for children with poly-juvenile idiopathic arthritis (JIA) and extended oligo JIA.
What is the current status of trial NCT00443430?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 85 participants. The study started on 2007-05. Estimated completion is 2010-10.
What conditions does trial NCT00443430 study?
This clinical trial studies the following conditions: Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis, Juvenile Chronic Polyarthritis.
What interventions are being tested in trial NCT00443430?
The interventions under investigation include: methotrexate (DRUG), methotrexate - etanercept - prednisolone arm (DRUG).
Who is sponsoring clinical trial NCT00443430?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00443430 being conducted?
This trial has 15 study locations across California, Massachusetts, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Idiopathic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00443430's enrollment target sits among peer trials
85 7th of 8 higher than 2 of 8 other Juvenile Idiopathic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Juvenile Idiopathic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
COMPLETED · Phase 4
-
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
RECRUITING · Phase 3
-
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
RECRUITING
-
Pain in Juvenile Arthritis
RECRUITING · NA
-
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
ACTIVE NOT RECRUITING
-
Juvenile Idiopathic Arthritis (JIA) Registry
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia